Yahoo Finance

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- ...

CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment

Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned ...
Yahoo Finance

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of ...
Nasdaq

CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation

Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
Nasdaq

CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...
Investopedia

Understanding Coupon Equivalent Rate (CER) for Fixed-Income Securities

Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Somer G. Anderson is CPA, doctor of accounting, ...